Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using Efungumab and amphotericin B colloid dispersion

J Pediatr Hematol Oncol. 2010 Mar;32(2):128-30. doi: 10.1097/MPH.0b013e3181cb49a8.

Abstract

Invasive fungal infections are serious complications of cancer therapy. We present a case report of a 12-year-old boy diagnosed with abdominal non-Hodgkin lymphoma and fecal and Candida peritonitis during induction chemotherapy. The invasive mycosis was managed using a combined approach of systemic antifungal agents including efungumab and surgical interventions. Efungumab, a recombinant antibody that inhibits extracellular heat shock protein 90, was used in combination with amphotericin B colloid dispersion after the failure of standard approaches.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Neoplasms / complications*
  • Abdominal Neoplasms / drug therapy
  • Amphotericin B / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antifungal Agents / administration & dosage*
  • Candidiasis / drug therapy*
  • Child
  • Drug Therapy, Combination
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • Humans
  • Lymphoma, Non-Hodgkin / complications*
  • Lymphoma, Non-Hodgkin / drug therapy
  • Male
  • Peritonitis / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antifungal Agents
  • HSP90 Heat-Shock Proteins
  • Amphotericin B
  • efungumab